Bob Darius has been appointed senior vice president, Quality Operations, Novavax, Inc. He will be responsible for leading the global Quality Operations, including both Quality Assurance and Quality Control, as well as serving as a member of the company’s senior management team. Novavax is a clinical-stage vaccine company focused on recombinant nanoparticle vaccines and adjuvants.
 
Mr. Darius has more than 25 years of experience in Quality Assurance, Quality Control and strategic manufacturing. He joins the company from GlaxoSmithKline Biologicals, where he served as vice president of Quality Operations. Mr. Darius provided oversight of the North American and German Vaccine Manufacturing Operations for more than 10 years and most recently transitioned to head Quality Advocacy Liaison.
 
Mr. Darius also held positions of increasing responsibility at the Food and Drug Administration, Center for Biologics Evaluation and Research, where he was a Senior Reviewer and Inspector, Advisor to the Deputy Center Director, Medicine, on counter-bioterrorism products.
 
“I am delighted to welcome Bob to the Novavax team,” said Stanley C. Erck, president and chief executive officer. “At this critical stage of our development, during which we are implementing our commercialization plans for our RSV F Vaccine, Bob’s depth of experience and understanding of evolving regulatory and quality requirements will be critical to our success.”